2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow AL 3789: new trials by email Literature Review of AL 3789 trials Research Report on AL 3789
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anecortave Acetate Risk-Reduction Trial (AART) Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg, Anecortave Acetate Vehicle - Dry AMD | Phase 3 | Terminated | Alcon Research | 2596 | 2004-03-01 | 2012-11-28 |
| Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL - Macular Degeneration | Phase 3 | Terminated | Alcon Research | 111 | 2003-06-01 | 2013-09-16 |
Alcon Research (2)
United States (2)
Patricia Zilliox (1) · Terry Wiernas, PhD (1)